This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Evidence for Prothrombin Time

Stephen T. Mennemeyer, PhD; James W. Winkelman, MD

JAMA. 1993;269(8):1030-1033.

Abstract
Objective.
—To determine if the occurrence of health outcomes following clinical laboratory testing can be used to identify types of laboratories that may be having higher than expected error rates.

Design.
—Retrospective analysis of Medicare Part B outpatient claims, Part A hospitalization bills, and death records using a case-control study.

Setting.
—Medicare records from six carrier territories were sampled during the period 1985 through 1987.

Patients.
—A total of 14 755 Medicare patients receiving a prothrombin time test in either a physician office laboratory or a commercial laboratory.

Outcome Measures.
—Occurrence of a hospitalization for stroke or acute myocardial infarction, death, or no adverse outcome within 6 days of a prothrombin time.

Results.
—In physician office laboratories where prothrombin time test volume is below 40 per month, the odds that a tested patient will experience a stroke or an acute myocardial infarction are up to 1.96 and 3.43 times greater, respectively, than for a similar patient tested in a commercial laboratory. Switching from one laboratory to another between successive prothrombin time tests increased the odds of a stroke or an acute myocardial infarction by 1.57 and 1.32, respectively. Patients in two states with strong laboratory regulatory programs had fewer adverse outcomes.

Conclusion.
—Examining patient outcomes subsequent to clinical laboratory testing may be a useful tool for clinical laboratory quality assurance.

(JAMA. 1993;269:1030-1033)

Author Affiliations
From the Department of Health Care Organization and Policy, School of Public Health, University of Alabama at Birmingham, and Abt Associates Inc, Cambridge, Mass (Dr Mennemeyer), and Brigham and Women's Hospital, and the Department of Pathology, Harvard University Medical School, Boston, Mass (Dr Winkelman).

Footnotes
Reprint requests to Department of Health Care Organization and Policy, University of Alabama at Birmingham School of Public Health, 118 Pickwick Place, UAB Station, Birmingham, AL 35294-2090 (Dr Mennemeyer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism
Ansell et al.
ASH Education Book 2000;2000:266-284.
ABSTRACT | FULL TEXT  

Are Physicians' Office Laboratory Results of Comparable Quality to Those Produced in Other Laboratory Settings?
Hurst et al.
JAMA 1998;279:468-471.
ABSTRACT | FULL TEXT  

Is It Time to Turn the Page on CLIA 1988?
Bachner
JAMA 1998;279:473-475.
FULL TEXT  

Screening for Clinical Laboratory Errors with Medicare Claims Data: Results for Digoxin
Winkelman and Mennemeyer
American Journal of Medical Quality 1996;11:25-32.
ABSTRACT  

Gauging the Accuracy of Laboratory Testing From Medicare Data
Venes
JAMA 1993;269:2985-2985.
ABSTRACT  

Gauging the Accuracy of Laboratory Testing From Medicare Data
Sacks
JAMA 1993;269:2984-2984.
ABSTRACT  

Gauging the Accuracy of Laboratory Testing From Medicare Data
Seeger
JAMA 1993;269:2984-2985.
ABSTRACT  

Gauging the Accuracy of Laboratory Testing From Medicare Data
Muscato
JAMA 1993;269:2985-2985.
ABSTRACT